| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Bruna Bernar Dias, Fernando Carreño, Victória Etges Helfer, Laura Ben Olivo, Keli Jaqueline Staudt, Karina Paese, Fabiano Barreto, Fabíola Schons Meyer, Ana Paula Herrmann, Sílvia Stanisçuaski Guterres, Stela Maris Kuze Rates, Bibiana Verlindo de Araújo, Iñaki F Trocóniz, Teresa Dalla Cost. Pharmacokinetic/pharmacodynamic modeling of cortical dopamine concentrations after quetiapine lipid core nanocapsules administration to schizophrenia phenotyped rats. CPT: pharmacometrics & systems pharmacology. 2024-01-29. PMID:38282365. |
pharmacokinetic/pharmacodynamic modeling of cortical dopamine concentrations after quetiapine lipid core nanocapsules administration to schizophrenia phenotyped rats. |
2024-01-29 |
2024-01-31 |
rat |
| Kazuyuki Nakagome, Hisateru Tachimori, Shiro Endo, Ken Murakami, Takaharu Azekawa, Seiji Hongo, Kazunari Niidome, Yoshitsugu Kojima, Sakiko Yamada, Hideki Oi, Tomiki Sumiyosh. A multicenter, single-arm, open-label interventional study of adherence to brexpiprazole during switching from previous antipsychotic drugs in patients with schizophrenia or schizoaffective disorder. Neuropsychopharmacology reports. 2024-01-22. PMID:38253334. |
the rate of medication persistence was examined in patients with schizophrenia or schizoaffective disorder during switching from previously administered antipsychotics to brexpiprazole, a new dopamine d |
2024-01-22 |
2024-01-25 |
Not clear |
| Smita Sahay, Emily A Devine, Robert E McCullumsmith, Sinead M O'Donova. Adenosine Receptor mRNA Expression in Frontal Cortical Neurons in Schizophrenia. Cells. vol 13. issue 1. 2024-01-11. PMID:38201235. |
schizophrenia is a devastating neuropsychiatric disorder associated with the dysregulation of glutamate and dopamine neurotransmitter systems. |
2024-01-11 |
2024-01-13 |
Not clear |
| Li Han, Yingkai Guo, Haohao Zhang, Zifan Wang, Fan Zhang, Yiran Wang, Xingqi Li, Ying Wang, Jiajia Y. Preparation of carbon quantum dot fluorescent probe from waste fruit peel and its use for the detection of dopamine. RSC advances. vol 14. issue 3. 2024-01-09. PMID:38192308. |
abnormal dopamine secretion can lead to diseases such as parkinson's disease and schizophrenia. |
2024-01-09 |
2024-01-10 |
human |
| Xiaomin Cui, Huiying Geng, Hong Zhang, Xinyang Sun, Lei Shang, Rongna Ma, Liping Jia, Chuan Li, Wei Zhang, Huaisheng Wan. A perylene diimide electrochemical probe with persulfate as a signal enhancer for dopamine sensing. The Analyst. 2024-01-08. PMID:38190154. |
dopamine (da) is an important biomarker related to parkinsonism, schizophrenia and renal disease. |
2024-01-08 |
2024-01-10 |
Not clear |
| Hao Chen, Xing-Xing Xiong, Shi-Yang Jin, Xiao-Ying He, Xiao-Wen Li, Jian-Ming Yang, Tian-Ming Gao, Yi-Hua Che. Dopamine D2 receptors in pyramidal neurons in the medial prefrontal cortex regulate social behavior. Pharmacological research. 2023-12-24. PMID:38142878. |
drugs acting on dopamine d2 receptors are widely used for the treatment of several neuropsychiatric disorders, including schizophrenia and depression. |
2023-12-24 |
2023-12-27 |
Not clear |
| David Castle, David Copolov, Bruce Singh, Tarun Bastiampilla. Seven decades of antipsychotic drugs: Why is the life of Australians with schizophrenia still so suboptimal? The Australian and New Zealand journal of psychiatry. 2023-12-22. PMID:38130026. |
the advent of dopamine (d2) receptor-blocking medications over 70 years ago, ushered in a new era of biological treatment for schizophrenia. |
2023-12-22 |
2023-12-24 |
Not clear |
| Kevin G O Ike, Sanne J C Lamers, Soumya Kaim, Sietse F de Boer, Bauke Buwalda, Jean-Christophe Billeter, Martien J H Ka. The human neuropsychiatric risk gene Drd2 is necessary for social functioning across evolutionary distant species. Molecular psychiatry. 2023-12-19. PMID:38114631. |
the drd2 gene, encoding the dopamine d2 receptor (d2r), was recently indicated as a potential target in the etiology of lowered sociability (i.e., social withdrawal), a symptom of several neuropsychiatric disorders such as schizophrenia and major depression. |
2023-12-19 |
2023-12-23 |
mouse |
| Dmytro I Boiko, Hitesh Chopra, Muhammad Bilal, Pavlo V Kydon, Larysa O Herasymenko, Vadym O Rud, Lesia A Bodnar, Ganna Yu Vasylyeva, Rustam I Isakov, Liliia V Zhyvotovska, Aashna Mehta, Andrii M Skrypniko. Schizophrenia and disruption of circadian rhythms: An overview of genetic, metabolic and clinical signs. Schizophrenia research. vol 264. 2023-12-15. PMID:38101179. |
the function of dopamine and adenosine in circadian rhythm should also be noted, as these hypotheses are considered to be the most popular theories explaining schizophrenia pathogenesis. |
2023-12-15 |
2023-12-18 |
Not clear |
| Xun Yang, Yuan Song, Yuhan Zou, Yilin Li, Jianguang Zen. Neural correlates of prediction error in patients with schizophrenia: evidence from an fMRI meta-analysis. Cerebral cortex (New York, N.Y. : 1991). 2023-12-07. PMID:38061699. |
we also found hyperactivity in frontal areas and hypoactivity in mesolimbic areas when encoding prediction error signals in schizophrenia patients, potentially indicating abnormal dopamine signaling of reward prediction error and suggesting failure to represent the value of alternative responses during prediction error learning and decision making. |
2023-12-07 |
2023-12-17 |
Not clear |
| Jin Oh Park, Yongheum Choi, Hyeong Min Ahn, Chang Ki Lee, Honggu Chun, Young Min Park, Kwang Bok Ki. Aggregation of Ag nanoparticle based on surface acoustic wave for surface-enhanced Raman spectroscopy detection of dopamine. Analytica chimica acta. vol 1285. 2023-12-06. PMID:38057052. |
dopamine (da), a vital neurotransmitter, plays a critical role in the human brain and relates to neuropsychiatric disorders such as parkinson's disease and schizophrenia. |
2023-12-06 |
2023-12-10 |
human |
| Yimin Yu, Jingjing He, Zhiwei Huang, Yan Li, Ying Wu, Yifeng Shen, Yanling Zhou, Cungang Bao, Zhiping Jin, Huafang L. Safety, tolerability, and pharmacokinetics of JX11502MA in Chinese healthy subjects: a first-in-human, randomized, double-blind, placebo-controlled study following single-dose administration. Expert opinion on investigational drugs. 2023-12-06. PMID:38054696. |
jx11502ma is a potent partial agonist of dopamine d2 and d3 receptors, with a preferential binding profile for d3 receptors in vitro, potentially for treating schizophrenia. |
2023-12-06 |
2023-12-10 |
human |
| Yosefu Arime, Yoshito Saitoh, Mikiko Ishikawa, Chikako Kamiyoshihara, Yasuo Uchida, Kazuki Fujii, Keizo Takao, Kazufumi Akiyama, Noriaki Ohkaw. Activation of prefrontal parvalbumin interneurons ameliorates working memory deficit even under clinically comparable antipsychotic treatment in a mouse model of schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2023-12-04. PMID:38049583. |
here, we used multi-dimensional approaches, including histological analysis of the prelimbic cortex (pl), lc-ms/ms-based in vivo dopamine d2 receptor occupancy analysis for antipsychotics, in vivo calcium imaging, and behavioral analyses of mice using chemogenetics to investigate neural mechanisms and potential therapeutic strategies for working memory deficit in a chronic phencyclidine (pcp) mouse model of schizophrenia. |
2023-12-04 |
2023-12-10 |
mouse |
| Brian Dea. Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal. Expert opinion on investigational drugs. 2023-11-23. PMID:37994870. |
successful phase 3 trials of karxt in people with schizophrenia is heralds a new era of treating the disorder with drugs that do not target the dopamine d2 receptor. |
2023-11-23 |
2023-11-29 |
Not clear |
| Sunah Choi, Minah Kim, Taekwan Kim, Eun-Jung Choi, Jungha Lee, Sun-Young Moon, Sang Soo Cho, Jongho Lee, Jun Soo Kwo. Fronto-striato-thalamic circuit connectivity and neuromelanin in schizophrenia: an fMRI and neuromelanin-MRI study. Schizophrenia (Heidelberg, Germany). vol 9. issue 1. 2023-11-09. PMID:37945576. |
changes in dopamine and fronto-striato-thalamic (fst) circuit functional connectivity are prominent in schizophrenia. |
2023-11-09 |
2023-11-20 |
Not clear |
| Lucila Bechelli, Eugenia Tomasella, Sofia Lopez Cardoso, Martina Belmonte, Diego M Gelma. Selective dopamine D2 receptor deletion from Nkx6.2 expressing cells causes impaired cognitive, motivation and anxiety phenotypes in mice. Scientific reports. vol 13. issue 1. 2023-11-09. PMID:37945756. |
abnormal dopamine neurotransmission is a common trait of some psychiatric diseases, like schizophrenia or bipolar disorder. |
2023-11-09 |
2023-11-20 |
mouse |
| Michael Davidson, William T Carpente. Targeted Treatment of Schizophrenia Symptoms as They Manifest, or Continuous Treatment to Reduce the Risk of Psychosis Recurrence. Schizophrenia bulletin. 2023-11-06. PMID:37929893. |
current pharmacological treatment of schizophrenia employs drugs that interfere with dopamine neurotransmission, aiming to suppress acute exacerbation of psychosis and maintenance treatment to reduce the risk of psychosis recurrence. |
2023-11-06 |
2023-11-08 |
Not clear |
| Millie Rincón-Cortés, Anthony A Grac. Sex-dependent emergence of prepubertal social dysfunction and augmented dopamine activity in a neurodevelopmental rodent model relevant for schizophrenia. Schizophrenia research. vol 262. 2023-11-03. PMID:37922841. |
sex-dependent emergence of prepubertal social dysfunction and augmented dopamine activity in a neurodevelopmental rodent model relevant for schizophrenia. |
2023-11-03 |
2023-11-08 |
rat |
| Alice Petty, Anna Garcia-Hidalgo, Els F Halff, Sridhar Natesan, Dominic J Withers, Elaine E Irvine, Michelle Kokkinou, Lisa A Wells, David R Bonsall, Sac-Pham Tang, Mattia Veronese, Oliver D Howe. Sub-Chronic Ketamine Administration Increases Dopamine Synthesis Capacity in the Mouse Midbrain: a Preclinical In Vivo PET Study. Molecular imaging and biology. 2023-10-23. PMID:37872462. |
there is robust evidence that people with schizophrenia show elevated dopamine (da) synthesis capacity in the striatum. |
2023-10-23 |
2023-11-08 |
mouse |
| Cátia Santa, Diana Rodrigues, Joana F Coelho, Sandra I Anjo, Vera M Mendes, Diogo Bessa-Neto, Michael J Dunn, David Cotter, Graça Baltazar, Patrícia Monteiro, Bruno Manada. Chronic treatment with D2-antagonist haloperidol leads to inhibitory/excitatory imbalance in striatal D1-neurons. Translational psychiatry. vol 13. issue 1. 2023-10-06. PMID:37803004. |
haloperidol is a typical antipsychotic medication used in the treatment of schizophrenia that is known to antagonize dopamine d2 receptors, which are abundantly expressed in the striatum. |
2023-10-06 |
2023-10-15 |
mouse |